Trails Edge Capital Partners LP Invests $1.66 Billion in ImageneBio, Inc. $IMA

Trails Edge Capital Partners LP purchased a new position in ImageneBio, Inc. (NASDAQ:IMA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 282,004 shares of the company’s stock, valued at approximately $1,663,824,000. Trails Edge Capital Partners LP owned 2.48% of ImageneBio at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IMA. Blue Owl Capital Holdings LP purchased a new stake in shares of ImageneBio in the second quarter valued at approximately $5,414,000. Deep Track Capital LP bought a new position in ImageneBio in the third quarter worth approximately $7,160,000. Cable Car Capital LP purchased a new position in ImageneBio during the 2nd quarter worth $4,611,000. Vanguard Group Inc. bought a new stake in ImageneBio during the 3rd quarter valued at $1,902,000. Finally, BlackRock Inc. purchased a new stake in shares of ImageneBio in the 2nd quarter worth $797,000. Institutional investors own 75.00% of the company’s stock.

ImageneBio Trading Down 1.2%

IMA opened at $5.55 on Wednesday. The firm has a market cap of $62.99 million, a price-to-earnings ratio of -1.21 and a beta of 0.76. ImageneBio, Inc. has a 12 month low of $3.94 and a 12 month high of $14.00. The stock has a fifty day moving average price of $5.79 and a 200-day moving average price of $5.83.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27. On average, equities research analysts forecast that ImageneBio, Inc. will post -3.23 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wedbush reissued an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. Wall Street Zen cut shares of ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, HC Wainwright assumed coverage on shares of ImageneBio in a report on Friday. They set a “buy” rating and a $28.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $29.00.

ImageneBio News Summary

Here are the key news stories impacting ImageneBio this week:

• Positive Sentiment: HC Wainwright initiated research coverage with a Buy rating and a $28 price target, substantially above the stock’s recent trading level. The firm expects ImageneBio to continue reporting losses but is maintaining a bullish view on the company’s longer-term prospects. ImageneBio Research Coverage Started at HC Wainwright
• Positive Sentiment: Reported short interest fell 87.2% to 49,297 shares as of August 14, representing only 0.4% of shares outstanding. The reduction lowers potential selling pressure and suggests fewer investors are betting against IMA, although the stock’s low trading volume limits the significance of the change.
• Neutral Sentiment: A separate report listed short interest at zero shares as of August 25, unchanged from zero previously. Because the report describes the change as “NaN” and conflicts with the August 14 figures, it appears to be a data-quality issue rather than a meaningful market development.
• Negative Sentiment: HC Wainwright’s detailed forecasts point to continued and potentially widening losses: EPS estimates are negative at $(3.57) for FY2026, $(5.48) for FY2027, and remain negative through FY2030. Persistent cash-burn and the absence of near-term profitability remain important risks, even with the firm’s Buy rating.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.